<DOC>
	<DOCNO>NCT00611676</DOCNO>
	<brief_summary>This single-blind , placebo-run-in trial . Subjects inform may receive Venlafaxine placebo course trial . All subject , fact , receive placebo first two week . All subject place 150-225 mg per day venlafaxine . Primary outcome assessment compare pain intensity 2 week ( placebo ) 12 week ( 10 week Venlafaxine treatment ) . Study Hypothesis : In subject continue activity-limiting osteoarthritis pain treatment acetaminophen non-steroidal anti-inflammatory agent , 150-225 mg Venlafaxine per day 10 week provide significant additional pain relief achieve placebo ( 30 % reduction Venlafaxine treatment ) .</brief_summary>
	<brief_title>A Single-Blind Placebo Run-In Study Venlafaxine Activity-Limiting Osteoarthritis Pain</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<criteria>Age 50 80 year Physician diagnosis OA hip , knee spine Significant activity limitation due pain least one month Western Ontario McMasters University Osteoarthritis Index ( WOMAC ) average pain 5/10 Brief Pain Inventory despite adequate treatment acetaminophen NSAIDs ( This identify OA group significant psychological distress desire treatment ) . Depression status restrict , monitor PRIMEMD interview SCL20 . We anticipate depressive symptom common population due requirement activity limitation . Can read write English Significant cognitive impairment History psychosis mania Current suicidal ideation Current substance abuse dependence Current use opioids antidepressant medication Use investigational drug within past month</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>osteoarthritis pain</keyword>
	<keyword>activity limitation</keyword>
	<keyword>antidepressant</keyword>
	<keyword>depression</keyword>
	<keyword>single-blind</keyword>
</DOC>